Garadacimab

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Advances in pharmacotherapy for children aged 2 to <12 years with hereditary angioedema: what is the current state of play?

Advances in pharmacotherapy for children aged 2 to <12 years with hereditary angioedema: what is the current state of play?

Journal: Expert opinion on pharmacotherapy

Published: October 28, 2026

Response to Letter to the Editor regarding "Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema".

Response to Letter to the Editor regarding "Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema".

Journal: Journal of comparative effectiveness research

Published: October 19, 2026

Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.

Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.

Journal: Journal of comparative effectiveness research

Published: October 19, 2026

Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema.

Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema.

Journal: Clinical and translational allergy

Published: June 03, 2026

Current and future therapies for bradykinin-mediated angioedema

Current and future therapies for bradykinin-mediated angioedema

Journal: Dermatologie (Heidelberg, Germany)

Published: May 27, 2026

Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.

Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.

Journal: Clinical and translational science

Published: April 30, 2026

Monoclonal antibodies in the management of hereditary angioedema.

Monoclonal antibodies in the management of hereditary angioedema.

Journal: Expert opinion on biological therapy

Published: April 28, 2026

Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies.

Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies.

Journal: The World Allergy Organization journal

Published: April 22, 2026

Factor XII in Thrombosis and Thromboinflammation: From Molecular Biology to Clinical Translation.

Factor XII in Thrombosis and Thromboinflammation: From Molecular Biology to Clinical Translation.

Journal: International journal of molecular sciences

Published: February 26, 2026

Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis.

Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis.

Journal: Advances in therapy

Published: February 23, 2026

Response to "Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema".

Response to "Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema".

Journal: Drugs in R&D

Published: January 12, 2026

Donidalorsen (Dawnzera) for prevention of hereditary angioedema attacks.

Donidalorsen (Dawnzera) for prevention of hereditary angioedema attacks.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Showing 1-12 of 48

Last Updated: 11/08/2026